What Does the FDA Drug Safety Law Mean for Drug Development?

If you have been reading the IN VIVO Blog you know what we think.

But why trust us?

That's why we've lined up a bunch of top R&D executives--like Pfizer's new R&D head Martin Mackay, Bristol's head of development Brian Daniels, and Glenn Gormley from Novartis--to talk about that at this year's FDA/CMS Summit for Biopharma Executives. It is just a month away: December 6-7 in Washington DC.

Our own Roger Longman will moderate a panel discussion among that group, tackling the big question: Did FDA kill the blockbuster?

And that is just one of more than 20 different sessions featuring top industry and government officials who will discuss all aspects of the new FDA law, as well as the new realities of reimbursement, Medicare Part D and the broader political landscape. All with an eye to helping you understand what it means for your business.

Why are we telling you this? Because we want you to come. Click here for more information.